Sign Up
SB 1528 Oregon Senate · 2026 Regular Session

Relating to health care.

Summary
] [ Requires the Oregon Health Authority to study health care. Directs the authority to submit findings to the interim committees of the Legislative Assembly related to health care no later than September 15, 2027. ] [ Sunsets on January 2, 2028. ] Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year. Becomes operative on January 1, 2028.
Bill status passed 3 of 5 stages cleared
Introduction
Feb 2026
Committee Review
Mar 2026
Senate Passage
Feb 2026
House Passage
Governor
Introduced Feb 2, 2026 Last action Mar 7, 2026
Maddy AI version diff · 1 comparison

What changed between versions

Introduced → A-Engrossed · 6 edits · Feb 25, 2026
MODERATE
The bill was amended from an Oregon Health Authority study on health care to a new requirement for drug manufacturers to report detailed pricing and cost information annually. This change significantly expands the bill's scope from a general health study to specific drug pricing transparency requirements.
Scope change
Changed from requiring a general health care study by OHA to requiring drug manufacturers to submit annual reports on pricing, costs, and patient assistance programs.
REQUIREMENT

Replaced the requirement for OHA to study health care with a requirement for drug manufacturers to report detailed information annually.

Added new reporting requirements for drug manufacturers to disclose pricing data, manufacturing costs, marketing expenses, R&D costs, sales revenue, profits, and patient assistance programs.

Removed the requirement for OHA to submit findings to legislative committees by September 15, 2027.

TIMELINE

Changed the effective date from January 2, 2028 (sunset date) to January 1, 2028 (start date), and established an annual reporting deadline of March 15.

DEFINITION

Added new statutory definitions for key terms including 'manufacture', 'manufacturer', 'new prescription drug', 'patient assistance program', 'prescription drug', and 'price'.

ELIGIBILITY

Added reporting threshold requiring drugs to cost $100 or more for a one-month supply or have a 10% or greater price increase to trigger reporting requirements.

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
11
Key actions
3
Committee
4
Mar 7, 2026
Lower · Passed
In committee upon adjournment.
lower
Feb 25, 2026
Committee
Referred to Rules.
lower
Feb 25, 2026
Introduced
First reading. Referred to Speaker's desk.
lower
Feb 25, 2026
Upper · Passed
Third reading. Carried by Patterson. Passed.
upper
Feb 20, 2026
Upper · Passed
Recommendation: Do pass with amendments. (Printed A-Eng.)
upper
Feb 2, 2026
Committee
Referred to Health Care.
upper
Feb 2, 2026
Introduced
Introduction and first reading. Referred to President's desk.
upper
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.